Sesen Bio, Inc. (SESN) News
Filter SESN News Items
SESN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SESN News Highlights
- For SESN, its 30 day story count is now at 4.
- Over the past 19 days, the trend for SESN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SESN are BIO, COOL and GNRC.
Latest SESN News From Around the Web
Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.
Sesen Bio Further Enhances Team with Key HiresCAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022. |
Lifshitz Law Firm, P.C. Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Katapult Holdings, Inc. (NASDAQGM: KPLT), PayPal Holdings, Inc. (NASDAQGS: PYPL), and SeSen Bio, Inc. (NASDAQGM: SESN)NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC) |
6 of the Best Penny Stocks Under $1 to Buy Now for 2022These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. |
Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited InvestorsSesen Bio Inc. (NASDAQ:SESN) traded at $0.89 at close of the session on Tuesday, 12/21/21, made an upward move of 1.99% on its previous days price. Looking at the stock we see that its previous close was $0.87 and the beta (5Y monthly) reads 0.50 with the days price range being $0.8525 $0.9008. In Sesen Bio Inc. (NASDAQ: SESN)s Gain Of 1.99% Profited Investors Read More » |
Zacks: Brokerages Anticipate Sesen Bio, Inc. (NASDAQ:SESN) to Post -$0.08 Earnings Per ShareEquities research analysts forecast that Sesen Bio, Inc. (NASDAQ:SESN) will report ($0.08) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sesen Bios earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.10). Sesen Bio posted earnings per share of ($0.07) during [] |
Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend?Sesen Bio Inc. (NASDAQ:SESN) price on Friday, December 10, fall -0.16% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.89. A look at the stocks price movement, the level at last check in todays session was $0.89, moving within a range at $0.8399 and $0.9499. The beta Sesen Bio Inc. (SESN) Has Recovered 21.35% From Its Low: Is This The Beginning Of A Trend? Read More » |
Sesen Bio reports anticipated regulatory path forward for Vicineum, shares down 18%No summary available. |
Why Sesen Bio Stock Got Slammed TodayThe biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design." |
Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder CancerSesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the FDA. Following the meeting, the Company has agreed to conduct a randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators' choice of intravesical chemotherapy. The trial may include both patients who have received adequate BCG and patients who have recei |
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™CAMBRIDGE, Mass., December 09, 2021--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting). |